Owing to major advances in the field of radiation oncology, patients with lung cancer can now receive technically individualized radiotherapy treatments. Nevertheless, in the era of precision oncology, radiotherapy-based treatment selection needs to be improved as many patients do not benefit or are not offered optimum therapies. Cost-effective robust biomarkers can address this knowledge gap and lead to individuals being offered more bespoke treatments leading to improved outcome. This narrative review discusses some of the current achievements and challenges in the realization of personalized radiotherapy delivery in patients with lung cancer.
Keywords: Lung cancer; Personalised medicine; Radiotherapy; Treatment response biomarkers.
Copyright © 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.